Publicador de continguts

Recerca, Salut materna, infantil i reproductiva

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

Durada
1/03/2018-28/02/2023
Coordinador
Clara Menéndez, ISGlobal
Finançadors
EDCTP

Malaria infection during pregnancy is an important driver of maternal and neonatal health especially among HIV infected women. In Africa, at least one million pregnancies are co-infected with malaria and HIV annually. The interaction between the two infections is particularly deleterious in pregnancy, leading to increased risk of malaria and HIV viral load, which may increase the frequency of mother to child transmission of HIV (MTCTHIV).

Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is recommended for malaria prevention in HIV-uninfected women but it is contraindicated in those HIV-infected on cotrimoxazole prophylaxis (CTXp) due to potential adverse effects. A recent EDCTP-funded trial showed that although an effective antimalarial (mefloquine) added to CTXp and long-lasting insecticide treated nets (LLITNs) in HIV-infected pregnant women improves malaria prevention and maternal health, it was not well tolerated and it was associated with an increase in HIV viral load at delivery and a two-fold increased risk of MTCT-HIV. Thus, this highlights the need to find alternative drugs with better tolerability and safety profile to prevent malaria in this vulnerable group and to further study the pharmacological interactions between antimalarial and antiretroviral (ARV) drugs.

Dihydroartemisinin-piperaquine (DHA-PPQ), has been shown to improve antimalarial protection in HIV-uninfected women constituting the most promising candidate for IPTp in HIV-infected pregnant women. However, there is limited information on the pharmacokinetics of DHA-PPQ with concomitant use of ARV drugs and CTX.

Objective

A randomized double blind placebo controlled trial to evaluate the safety and efficacy of DHA-PPQ for IPTp in HIV-infected pregnant women receiving CTXp and ARV drugs and using LLITNs will be conducted in Gabon and Mozambique where malaria and HIV infection are moderate to highly prevalent. The possibility of a pharmacokinetic interaction between DHA-PPQ and ARV drugs will be assessed. Women will receive ARV therapy according to national guidelines and their infants will be followed until one year of age to evaluate the impact of DHA-PPQ on MTCT-HIV.

This 5-year project, funded by EDCTP and coordinated by ISGlobal in collaboration with the Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon), the Manhiça Health Research Center/ Fundaçao Manhiça (CISM/FM, Mozambique), the Medical University of Vienna (MedUni Wien, Austria), the Bernhard Nocht Institut für Tropenmedizin (BNITM, Germany), and the Eberhard Karls Universitaet Tuebingen (EKUT, Germany) will provide conclusive evidence to reduce the burden of two of the most important poverty-related diseases (PRDs), in HIV-infected pregnant women exposed to malaria.

Total funding

2,985,000 €

“This project is part of the EDCTP2 programme supported by the European Union”

With the support of:


This project is part of the EDCTP2 programme supported by the European Union

Altres projectes

Veure projectes passats

MA-CoV

Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations

COMBACTE

Combatent la Resistència Bacteriana a Europa

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias

CaDMIA-plus

Validación continuada de la autopsia mínimamente invasiva (MIA) para la investigación de la causa de muerte en niños pequeños, y desarrollo de un centro de investigación y formación sobre el estudio de la causa de muerte

MIBio

Identification of Prematurity and Pre-Eclampsia as Causes of Mortality

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

IPERVAC-SL

Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone

RESPIRE

Respiratory syncytial virus (RSV) in African pregnant women and children

VITAL

Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance

HIV drug resistance (HIVDR)

Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique

PROTECT

PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa